Forefront Analytics LLC bought a new position in shares of Immatics (NASDAQ:IMTX – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,987 shares of the company’s stock, valued at approximately $139,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Trexquant Investment LP lifted its holdings in shares of Immatics by 4.2% during the fourth quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after purchasing an additional 1,801 shares during the period. AlphaCentric Advisors LLC increased its holdings in Immatics by 14.3% in the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after purchasing an additional 2,500 shares during the period. Nan Fung Group Holdings Ltd acquired a new stake in shares of Immatics in the first quarter valued at about $165,000. The Manufacturers Life Insurance Company increased its stake in shares of Immatics by 13.9% in the second quarter. The Manufacturers Life Insurance Company now owns 150,769 shares of the company’s stock valued at $1,752,000 after buying an additional 18,354 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in shares of Immatics during the fourth quarter worth about $232,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.
Immatics Price Performance
Shares of NASDAQ IMTX opened at $11.73 on Friday. The company has a market capitalization of $993.04 million, a PE ratio of -11.07 and a beta of 0.75. Immatics has a twelve month low of $7.15 and a twelve month high of $13.77. The firm has a fifty day simple moving average of $11.73 and a 200 day simple moving average of $11.55.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.
Check Out Our Latest Stock Analysis on Immatics
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Articles
- Five stocks we like better than Immatics
- How to Calculate Inflation Rate
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Buy P&G Now, Before It Sets A New All-Time High
- MarketBeat Week in Review – 9/23 – 9/27
- Upcoming IPO Stock Lockup Period, Explained
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics (NASDAQ:IMTX – Free Report).
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.